The global healthcare industry today is worth several trillion dollars, and there is constant competition among pharmaceutical firms to be the first to develop, test and market new drugs.  

However, the pharmaceutical industry is a challenging place in which to work.  Before it reaches the open market, any drug must undergo rigorous testing to ensure its safety and efficacy.  Initially, it will be tested synthetically and in preclinical trials.  Depending on the results, it may then be approved for Phase I human testing.  If it still appears effective and shows a good safety profile, the drug may then be allowed to progress to Phase II and finally Phase III.  Only if the developers can demonstrate across a large population sample that the drug is better than what is already available, may they submit a regulatory marketing application.

Only one in over six thousand compounds is ever approved.  Many fail for technical reasons, but even those drugs which are proven by scientific data to be effective may prove to be too expensive to manufacture to be commercially viable.  If a drug reaches the open market, it must then be marketed in a manner that encourages doctors to prescribe it and patients to take it.  In many countries, there is the additional challenge of presenting the drug as cost-effective when prescribed by national health services.

One of the challenges of pharmaceutical PR is to celebrate the innovations and achievements of pharmaceutical companies, while also offering advice and support when things don’t go so well.  At Tudor Reilly we have years of experience in communicating the good news, but we can also ensure that any bad news is communicated with clarity and honesty.

Find out more about our healthcare pr services.

<< Back to What we do                                                                                                                                                            To Digital media >>